Dashboard
Manage Tickers

CDXCChromaDex Corp.

Nasdaq chromadex.com


$ 3.69 $ -0.10 (-2.64 %)    

Friday, 19-Apr-2024 15:59:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 414.59 $ -8.76 (-2.07 %)
DIA $ 379.83 $ 1.96 (0.52 %)
SPY $ 494.96 $ -4.36 (-0.87 %)
TLT $ 89.15 $ 0.32 (0.36 %)
GLD $ 221.02 $ 0.69 (0.31 %)
$ 3.69
$ 3.78
$ 0.00 x 0
$ 3.71 x 200
$ 3.62 - $ 3.90
$ 1.25 - $ 4.65
308,734
na
276.69M
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-06-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-08-2023 12-31-2022 10-K
6 11-02-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-14-2022 12-31-2021 10-K
10 11-03-2021 09-30-2021 10-Q
11 08-03-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-12-2021 12-31-2020 10-K
14 11-04-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-18-2020 03-31-2020 10-Q
17 03-10-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 03-07-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-15-2018 12-30-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-10-2017 07-01-2017 10-Q
28 05-11-2017 04-01-2017 10-Q
29 03-16-2017 12-31-2016 10-K
30 11-10-2016 10-01-2016 10-Q
31 08-11-2016 07-02-2016 10-Q
32 05-12-2016 04-02-2016 10-Q
33 03-17-2016 01-02-2016 10-K
34 11-12-2015 10-03-2015 10-Q
35 08-13-2015 07-04-2015 10-Q
36 05-14-2015 04-04-2015 10-Q
37 03-19-2015 01-03-2015 10-K
38 11-06-2014 09-27-2014 10-Q
39 08-12-2014 06-28-2014 10-Q
40 05-08-2014 03-29-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

roth-mkm-maintains-buy-on-chromadex-raises-price-target-to-6
Roth MKM Maintains Buy on ChromaDex, Raise...
04/09/2024 13:59:19

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target from $4.25 to $6.

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
03/18/2024 17:31:33

hc-wainwright--co-maintains-buy-on-chromadex-raises-price-target-to-6
HC Wainwright & Co. Maintains Buy on Chrom...
03/11/2024 11:23:13

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target ...

chromadex-expects-trajectory-of-2024-revenue-growth-to-continue-projecting-higher-rate-of-revenue-growth-than-prior-year-growth-of-16
ChromaDex Expects Trajectory Of 2024 Reven...
03/06/2024 21:23:13

chromadex-q4-eps-000-beats-003-estimate-sales-2120m-beat-2098m-estimate
ChromaDex Q4 EPS $0.00 Beats $(0.03) Estim...
03/06/2024 21:05:14

ChromaDex (NASDAQ:CDXC) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.03) by ...

earnings-scheduled-for-march-6-2024
Earnings Scheduled For March 6, 2024
03/06/2024 10:00:02

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue o...

earnings-preview-for-chromadex
Earnings Preview For ChromaDex
03/05/2024 16:02:12

neurohacker-collective-and-chromadex-partner-to-optimize-cellular-health-with-the-debut-of-qualia-nad
Neurohacker Collective And ChromaDex Partn...
12/12/2023 15:31:51

Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Catego...

a-milestone-phase-i-randomized-double-blind-clinical-trial-demonstrates-high-dose-niagen-patented-nicotinamide-riboside-supplementation-induces-a-potent-nad-response-and-is-associated-with-mild-improvement-in-parkinsons-disease
A Milestone Phase I Randomized, Double-Bli...
11/30/2023 13:36:08

Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical stu...

chromadex-new-published-phase-ii-clinical-study-demonstrates-that-supplementation-with-niagen-patented-nicotinamide-riboside-elevates-nad-up-to-fourfold-improving-motor-coordination-and-eye-movement-in-ataxia-telangiectasia-patients
ChromaDex New Published Phase II Clinical ...
11/15/2023 13:35:12

This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well...

chromadex-q3-earnings-insights
ChromaDex: Q3 Earnings Insights
11/08/2023 21:50:33

chromadex-q3-2023-gaap-eps-001-beats-003-estimate-sales-1950m-miss-2025m-estimate
ChromaDex Q3 2023 Gaap EPS $(0.01) Beats $...
11/08/2023 21:46:41

ChromaDex (NASDAQ:CDXC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by ...

earnings-scheduled-for-november-8-2023
Earnings Scheduled For November 8, 2023
11/08/2023 09:21:00

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

earnings-outlook-for-chromadex
Earnings Outlook For ChromaDex
11/07/2023 15:01:50

chromadex-debuts-clinical-strength-tru-niagen-pro-1000mg-featuring-niagen-one-of-the-most-efficient-nicotinamide-adenine-dinucleotide-boosters-available-to-consumers-nationwide
ChromaDex Debuts Clinical Strength Tru Nia...
11/01/2023 12:42:27

Tru Niagen® Pro 1,000mg is recommended by physicians and used by pro-athletes as it is clinically proven to boost NAD+ levels b...

chromadex-shares-result-from-a-clinical-study-revealing-that-elevating-nicotinamide-adenine-dinucleotide-with-nicotinamide-riboside-supplementation-reduces-inflammation-in-healthy-subjects-and-immune-cells-derived-from-psoriasis-patients
ChromaDex Shares Result From A Clinical St...
10/02/2023 12:34:25

Celebrating a significant achievement in NAD+ research, these findings contribute to the mounting evidence indicating that NR m...

chromadex-shares-findings-from-a-preclinical-study-shows-exogenous-nicotinamide-mononucleotide-must-be-converted-to-nicotinamide-riboside-making-nr-a-more-efficient-nicotinamide-adenine-dinucleotide-precursor-to-nmn
ChromaDex Shares Findings From A Preclinic...
08/24/2023 12:42:39

This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane dire...

hc-wainwright--co-reiterates-buy-on-chromadex-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Chro...
08/10/2023 11:50:13

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $5 price target.

chromadex-sees-fy23-revenue-growth-at-least-15
ChromaDex Sees FY23 Revenue Growth At Leas...
08/09/2023 21:41:45

chromadex-q2-eps-003-beats-004-estimate-sales-2032m-beat-1919m-estimate
ChromaDex Q2 EPS $(0.03) Beats $(0.04) Est...
08/09/2023 20:50:59

ChromaDex (NASDAQ:CDXC) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

04/22/2024 Dick's Sporting Goods, Inc. (DKS)
04/22/2024 Innodata Inc. (INOD)
04/22/2024 Fox Factory Holding Corp. (FOXF)
04/23/2024 Lantronix, Inc. (LTRX)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)